Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Selective and state-dependent activation of TRESK (K2P 18.1) background potassium channel by cloxyquin.
Lengyel M
,
Dobolyi A
,
Czirják G
,
Enyedi P
.
???displayArticle.abstract???
BACKGROUND AND PURPOSE: Cloxyquin (5-cloroquinolin-8-ol) has been described as an activator of TRESK (K2P 18.1, TWIK-related spinal cord K+ channel) background potassium channel. We have examined the specificity of the drug by testing several K2P channels. We have investigated the mechanism of cloxyquin-mediated TRESK activation, focusing on the differences between the physiologically relevant regulatory states of the channel.
EXPERIMENTAL APPROACH: Potassium currents were measured by two-electrode voltage clamp in Xenopus oocytes and by whole-cell patch clamp in mouse dorsal root ganglion (DRG) neurons.
KEY RESULTS: Cloxyquin (100 µM) activated mouse and human TRESK 4.4 ± 0.3 (n = 28) and 3.9 ± 0.3-fold (n = 8), respectively. The drug selectively targeted TRESK in the K2P channel family and exerted state-dependent effects. TRESK was potently activated by cloxyquin in the resting state. However, after robust activation of the current by the calcium signal, evoked by stimulation of Gq-coupled receptors, the compound did not influence mouse TRESK and only slightly affected the human channel. The constitutively active mutant channels, mimicking the dephosphorylated state (S276A) or containing altered channel pore (F156A and F364A), were not further stimulated by cloxyquin. In a subpopulation of isolated DRG neurons, cloxyquin substantially activated the background potassium current.
CONCLUSIONS AND IMPLICATIONS: Cloxyquin activates TRESK by a Ca2+ /calcineurin-independent mechanism. The drug is specific for TRESK within the K2P channel family and useful for studying TRESK currents in native cells. The state-dependent pharmacological profile of this channel should be considered in the development of therapeutics for migraine and other nociceptive disorders.
Alexander,
The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels.
2015, Pubmed
Alexander,
The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels.
2015,
Pubmed
Alexander,
The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors.
2015,
Pubmed
Bautista,
Pungent agents from Szechuan peppers excite sensory neurons by inhibiting two-pore potassium channels.
2008,
Pubmed
Beltrán,
The pungent substances piperine, capsaicin, 6-gingerol and polygodial inhibit the human two-pore domain potassium channels TASK-1, TASK-3 and TRESK.
2013,
Pubmed
,
Xenbase
Braun,
TRESK background K(+) channel is inhibited by PAR-1/MARK microtubule affinity-regulating kinases in Xenopus oocytes.
2011,
Pubmed
,
Xenbase
Braun,
Differential sensitivity of TREK-1, TREK-2 and TRAAK background potassium channels to the polycationic dye ruthenium red.
2015,
Pubmed
,
Xenbase
Brohawn,
Crystal structure of the human K2P TRAAK, a lipid- and mechano-sensitive K+ ion channel.
2012,
Pubmed
Bruner,
Identification of novel small molecule modulators of K2P18.1 two-pore potassium channel.
2014,
Pubmed
Curtis,
Experimental design and analysis and their reporting: new guidance for publication in BJP.
2015,
Pubmed
Czirják,
TRESK background K(+) channel is inhibited by phosphorylation via two distinct pathways.
2010,
Pubmed
,
Xenbase
Czirják,
Zinc and mercuric ions distinguish TRESK from the other two-pore-domain K+ channels.
2006,
Pubmed
,
Xenbase
Czirják,
Targeting of calcineurin to an NFAT-like docking site is required for the calcium-dependent activation of the background K+ channel, TRESK.
2006,
Pubmed
,
Xenbase
Czirják,
The LQLP calcineurin docking site is a major determinant of the calcium-dependent activation of human TRESK background K+ channel.
2014,
Pubmed
Czirják,
The two-pore domain K+ channel, TRESK, is activated by the cytoplasmic calcium signal through calcineurin.
2004,
Pubmed
,
Xenbase
Czirják,
Formation of functional heterodimers between the TASK-1 and TASK-3 two-pore domain potassium channel subunits.
2002,
Pubmed
,
Xenbase
Enyedi,
Properties, regulation, pharmacology, and functions of the K₂p channel, TRESK.
2015,
Pubmed
,
Xenbase
Enyedi,
Molecular background of leak K+ currents: two-pore domain potassium channels.
2010,
Pubmed
GHOLZ,
PROPHYLAXIS AND THERAPY OF AMEBIASIS AND SHIGELLOSIS WITH IODOCHLORHYDROXYQUIN.
1964,
Pubmed
Hongmanee,
In vitro activities of cloxyquin (5-chloroquinolin-8-ol) against Mycobacterium tuberculosis.
2007,
Pubmed
Kang,
Lamotrigine inhibits TRESK regulated by G-protein coupled receptor agonists.
2008,
Pubmed
Kang,
TREK-2 (K2P10.1) and TRESK (K2P18.1) are major background K+ channels in dorsal root ganglion neurons.
2006,
Pubmed
Kilkenny,
Animal research: reporting in vivo experiments: the ARRIVE guidelines.
2010,
Pubmed
Kim,
Identification of blocker binding site in mouse TRESK by molecular modeling and mutational studies.
2013,
Pubmed
Lafrenière,
A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura.
2010,
Pubmed
Lengyel,
Selective and state-dependent activation of TRESK (K2P 18.1) background potassium channel by cloxyquin.
2018,
Pubmed
,
Xenbase
Lengyel,
Formation of Functional Heterodimers by TREK-1 and TREK-2 Two-pore Domain Potassium Channel Subunits.
2016,
Pubmed
,
Xenbase
Liu,
Functional analysis of a migraine-associated TRESK K+ channel mutation.
2013,
Pubmed
,
Xenbase
Mathie,
Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain.
2015,
Pubmed
McGrath,
Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP.
2015,
Pubmed
Miller,
Crystal structure of the human two-pore domain potassium channel K2P1.
2012,
Pubmed
Monteillier,
Investigation of the structure activity relationship of flufenamic acid derivatives at the human TRESK channel K2P18.1.
2016,
Pubmed
Oliveri,
8-Hydroxyquinolines in medicinal chemistry: A structural perspective.
2016,
Pubmed
Park,
Effects of analgesics and antidepressants on TREK-2 and TRESK currents.
2016,
Pubmed
Sano,
A novel two-pore domain K+ channel, TRESK, is localized in the spinal cord.
2003,
Pubmed
Southan,
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.
2016,
Pubmed
Tulleuda,
TRESK channel contribution to nociceptive sensory neurons excitability: modulation by nerve injury.
2011,
Pubmed
Veale,
Aristolochic acid, a plant extract used in the treatment of pain and linked to Balkan endemic nephropathy, is a regulator of K2P channels.
2016,
Pubmed
Wright,
Cloxyquin (5-chloroquinolin-8-ol) is an activator of the two-pore domain potassium channel TRESK.
2013,
Pubmed
Yamamoto,
Immunohistochemical colocalization of TREK-1, TREK-2 and TRAAK with TRP channels in the trigeminal ganglion cells.
2009,
Pubmed
Yoo,
Regional expression of the anesthetic-activated potassium channel TRESK in the rat nervous system.
2009,
Pubmed
Zhang,
The cardioprotective compound cloxyquin uncouples mitochondria and induces autophagy.
2016,
Pubmed
